(+/-)-3-Phthalimido-glutarsaeure-monoamid | 91956-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (+/-)-3-Phthalimido-glutarsaeure-monoamid
• 英文别名: DL-3-Phthalimido-glutarsaeure-monoamid；4-carbamoyl-3-phthalimido-butyric acid；5-Amino-3-(1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid
• CAS: 91956-01-3
• 化学式: C₁₃H₁₂N₂O₅
• 分子量: 276.249
• InChiKey: PIVOPPUUEMDEKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• RECTAL APPLICATION OF THALIDOMIDE IN PATIENTS WITH HEMORRHAGIC CHRONIC RADIATION PROCTITIS
  申请人：Vonnahme, Franz Josef

  公开号：EP3915556A1

  公开（公告）日：2021-12-01

  Hemorrhagic chronic radiation proctitis is a long-term side effect of radiotherapy in the treatment of pelvic malignancies. The present invention pertains to the therapeutic use of thalidomide or an analogue thereof for treating hemorrhagic chronic radiation proctitis, wherein said treatment comprises rectally administering said thalidomide or its analogue to a patient in need thereof. Topical treatment of the areas affected by hemorrhagic chronic radiation proctitis with thalidomide leads to a long lasting decay of the hemorrhagic chronic radiation proctitis and healing of the affected tissue.

  出血性慢性放射性直肠炎是盆腔恶性肿瘤放疗的一种长期副作用。本发明涉及沙利度胺或其类似物治疗出血性慢性放射性直肠炎的治疗用途，其中所述治疗包括向有需要的患者直肠给药所述沙利度胺或其类似物。用沙利度胺局部治疗受出血性慢性放射性直肠炎影响的部位，可使出血性慢性放射性直肠炎长期缓解，受影响的组织愈合。
• Methods and Compositions for Inhibition of Angiogenesis
  申请人：D'Amato Robert J.

  公开号：US20090036412A1

  公开（公告）日：2009-02-05

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
• US8039488B2
  申请人：——

  公开号：US8039488B2

  公开（公告）日：2011-10-18